Table 1.

Immunotherapy plus Chemotherapy.

STUDY (#=non cited in the text) REF	AGENTS	PHASE	SETTING	%MSS	PRIMARY ENDPOINTS	RESULTS * *In the experimental arm when applicable
NCT03832621 MAYA trial (22)	nivolumab + ipilimumab + temozolomide	II	Metastatic or inoperable MSS -MGMT silenced, I line	100	8 months PFS rate	36%
NCT03519412	temozolomide + pembrolizumab	II	Metastatic, I line	100	ORR	Ongoing
NCT03721653 ATEZOTRIBE (23)	FOLFOXIRI + bevacizumab + atezolizumab	II	Unresectable, I line	94	PFS	13.1 months
NCT03414983 Checkmate9x8 (24)	mFOLFOX + bevacizumab ± nivolumab	II	Unresectable metastatic, I line	NA	PFS	11.9 months
NCT02860546 (25)	trifluridine/tipiracil + nivolumab	II	Metastatic or locally advanced, II line and beyond	100	irORR	0%
NCT05229003#	anlotinib + irinotecan and anlotinib + penpulimab + irinotecan	II	Recurrent/metastatic, II line and beyond	NA	ORR	Ongoing
NCT04866862#	fruquintinib + camrelizumab	II	Metastatic, III line	NA	ORR	Ongoing
NCT04262687#	capecitabine + oxaliplatin + bevacizumab + pembrolizumab	III	Metastatic, I line	NA	10 months OS	Ongoing

NA, not available.